Literature DB >> 29365322

Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis.

Neethu Menon1, Ravi Sarode2, Ayesha Zia1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29365322      PMCID： PMC5787863          DOI： 10.1182/bloodadvances.2017012047

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  22 in total

Review 1.  Hereditary protein C deficiency: a review of the genetics, clinical presentation, diagnosis and treatment.

Authors:  R A Marlar; S Mastovich
Journal:  Blood Coagul Fibrinolysis       Date:  1990-08       Impact factor: 1.276

2.  Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.

Authors:  Meyer Michel Samama; Jean-Luc Martinoli; Léna LeFlem; Céline Guinet; Geneviève Plu-Bureau; François Depasse; Elisabeth Perzborn
Journal:  Thromb Haemost       Date:  2010-02-02       Impact factor: 5.249

3.  The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability.

Authors:  S Wielders; M Mukherjee; J Michiels; D T Rijkers; J P Cambus; R W Knebel; V Kakkar; H C Hemker; S Béguin
Journal:  Thromb Haemost       Date:  1997-04       Impact factor: 5.249

4.  Anticoagulation therapy for thromboembolism prevention: a case of warfarin-induced skin necrosis in the setting of protein C deficiency.

Authors:  Jonathan Lai; Daryl Ramai; Ramiz Alchi; Dennis Bloomfield
Journal:  BMJ Case Rep       Date:  2017-05-12

Review 5.  Coumarin necrosis, neonatal purpura fulminans, and protein C deficiency.

Authors:  C L Gladson; P Groncy; J H Griffin
Journal:  Arch Dermatol       Date:  1987-12

6.  Effects of antiplatelet agents on platelet-induced thrombin generation.

Authors:  W Wegert; J Graff; D Kaiser; H K Breddin; U Klinkhardt; S Harder
Journal:  Int J Clin Pharmacol Ther       Date:  2002-04       Impact factor: 1.366

7.  Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.

Authors:  Shanshan Du; Job Harenberg; Sandra Krämer; Roland Krämer; Martin Wehling; Christel Weiss
Journal:  Ther Drug Monit       Date:  2015-06       Impact factor: 3.681

Review 8.  Assays for measuring rivaroxaban: their suitability and limitations.

Authors:  Edelgard Lindhoff-Last; Meyer Michel Samama; Thomas L Ortel; Jeffrey I Weitz; Theodore E Spiro
Journal:  Ther Drug Monit       Date:  2010-12       Impact factor: 3.681

9.  Calibrated automated thrombin generation measurement in clotting plasma.

Authors:  H Coenraad Hemker; Peter Giesen; Raed Al Dieri; Véronique Regnault; Eric de Smedt; Rob Wagenvoord; Thomas Lecompte; Suzette Béguin
Journal:  Pathophysiol Haemost Thromb       Date:  2003

10.  Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time.

Authors:  R al Dieri; S Alban; S Béguin; H Coenraad Hemker
Journal:  J Thromb Haemost       Date:  2004-08       Impact factor: 5.824
View more
  3 in total

1.  Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: A case report.

Authors:  Momoka Kamada; Tsuneaki Kenzaka
Journal:  World J Clin Cases       Date:  2019-12-26       Impact factor: 1.337

2.  Multiple arterial and venous thromboembolism in a male patient with hereditary protein C deficiency: A case report.

Authors:  Likun Sun; Xin Li; Quanming Li; Lunchang Wang; Jiehua Li; Chang Shu
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

Review 3.  Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.

Authors:  Lina Khider; Nicolas Gendron; Laetitia Mauge
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.